Matt O'Brien
Stock Analyst at Piper Sandler
(2.43)
# 1,387
Out of 4,479 analysts
121
Total ratings
45.36%
Success rate
-1.93%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Upgrades: Overweight | $205 → $245 | $211.25 | +15.98% | 3 | Jul 1, 2024 | |
| CUTR Cutera | Maintains: Neutral | $3 | $1.35 | +122.22% | 6 | Jun 21, 2024 | |
| GMED Globus Medical | Upgrades: Overweight | $60 → $80 | $68.05 | +17.56% | 6 | May 20, 2024 | |
| RCEL AVITA Medical | Downgrades: Neutral | $21 → $9 | $7.88 | +14.21% | 6 | May 14, 2024 | |
| TELA TELA Bio | Reiterates: Overweight | $12 → $10 | $4.61 | +116.92% | 3 | May 10, 2024 | |
| FNA Paragon 28 | Reiterates: Overweight | $18 → $15 | $6.62 | +126.59% | 3 | May 9, 2024 | |
| PEN Penumbra | Maintains: Overweight | $290 → $260 | $175.99 | +47.74% | 8 | May 8, 2024 | |
| STAA STAAR Surgical Company | Maintains: Neutral | $33 → $40 | $44.52 | -10.15% | 6 | May 8, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $67 → $75 | $63.16 | +18.75% | 2 | May 6, 2024 | |
| SGHT Sight Sciences | Reiterates: Neutral | $5 → $6 | $6.16 | -2.60% | 5 | May 3, 2024 | |
| TNDM Tandem Diabetes Care | Reiterates: Overweight | $35 → $50 | $39.15 | +27.71% | 6 | May 3, 2024 | |
| TMDX TransMedics Group | Reiterates: Overweight | $95 → $120 | $148.97 | -19.45% | 2 | May 1, 2024 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $33 → $15 | $11.78 | +27.33% | 5 | May 1, 2024 | |
| SYK Stryker | Maintains: Overweight | $375 → $380 | $334.30 | +13.67% | 7 | May 1, 2024 | |
| CNMD CONMED | Maintains: Overweight | $100 → $95 | $67.04 | +41.71% | 7 | Apr 25, 2024 | |
| SIBN SI-BONE | Initiates: Overweight | $25 | $13.00 | +92.31% | 1 | Mar 28, 2024 | |
| PODD Insulet | Maintains: Overweight | $250 → $230 | $197.19 | +16.64% | 6 | Feb 23, 2024 | |
| GKOS Glaukos | Maintains: Overweight | $90 → $105 | $118.98 | -11.75% | 6 | Dec 22, 2023 | |
| DXCM DexCom | Maintains: Overweight | $135 → $150 | $112.49 | +33.35% | 8 | Dec 19, 2023 | |
| HUMA Humacyte | Maintains: Neutral | $3.5 → $3 | $5.11 | -41.29% | 2 | Nov 10, 2023 | |
| APYX Apyx Medical | Maintains: Overweight | $4 → $4.5 | $1.34 | +235.82% | 2 | Aug 11, 2023 | |
| BSX Boston Scientific | Maintains: Overweight | $58 → $62 | $76.55 | -19.01% | 2 | Jul 6, 2023 | |
| UTRS Minerva Surgical | Maintains: Overweight | $100 → $20 | $1.48 | +1,251.35% | 5 | May 3, 2023 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Overweight | n/a | $106.27 | - | 2 | Mar 10, 2023 | |
| OBIO Orchestra BioMed Holdings | Initiates: Overweight | $15 | $7.44 | +101.61% | 1 | Feb 24, 2023 | |
| ITGR Integer Holdings | Initiates: Overweight | $85 | $115.75 | -26.57% | 1 | Feb 24, 2023 | |
| MOTS Motus GI Holdings | Maintains: Overweight | $150 → $90 | $0.04 | +212,164.15% | 1 | Nov 15, 2022 | |
| ATRC AtriCure | Maintains: Overweight | $90 → $55 | $22.39 | +145.65% | 1 | Aug 3, 2022 | |
| MDT Medtronic | Maintains: Neutral | $105 → $100 | $77.37 | +29.25% | 3 | May 27, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $93 → $109 | $86.51 | +25.71% | 1 | Feb 11, 2021 | |
| ZYXI Zynex | Downgrades: Neutral | n/a | $9.07 | - | 2 | Jan 29, 2021 | |
| BAX Baxter International | Downgrades: Neutral | n/a | $32.85 | - | 1 | Jan 29, 2021 | |
| KRMD KORU Medical Systems | Initiates: Overweight | n/a | $2.27 | - | 1 | Jun 24, 2020 |
Teleflex
Jul 1, 2024
Upgrades: Overweight
Price Target: $205 → $245
Current: $211.25
Upside: +15.98%
Cutera
Jun 21, 2024
Maintains: Neutral
Price Target: $3
Current: $1.35
Upside: +122.22%
Globus Medical
May 20, 2024
Upgrades: Overweight
Price Target: $60 → $80
Current: $68.05
Upside: +17.56%
AVITA Medical
May 14, 2024
Downgrades: Neutral
Price Target: $21 → $9
Current: $7.88
Upside: +14.21%
TELA Bio
May 10, 2024
Reiterates: Overweight
Price Target: $12 → $10
Current: $4.61
Upside: +116.92%
Paragon 28
May 9, 2024
Reiterates: Overweight
Price Target: $18 → $15
Current: $6.62
Upside: +126.59%
Penumbra
May 8, 2024
Maintains: Overweight
Price Target: $290 → $260
Current: $175.99
Upside: +47.74%
STAAR Surgical Company
May 8, 2024
Maintains: Neutral
Price Target: $33 → $40
Current: $44.52
Upside: -10.15%
PROCEPT BioRobotics
May 6, 2024
Maintains: Overweight
Price Target: $67 → $75
Current: $63.16
Upside: +18.75%
Sight Sciences
May 3, 2024
Reiterates: Neutral
Price Target: $5 → $6
Current: $6.16
Upside: -2.60%
Tandem Diabetes Care
May 3, 2024
Reiterates: Overweight
Price Target: $35 → $50
Current: $39.15
Upside: +27.71%
TransMedics Group
May 1, 2024
Reiterates: Overweight
Price Target: $95 → $120
Current: $148.97
Upside: -19.45%
CVRx, Inc.
May 1, 2024
Maintains: Overweight
Price Target: $33 → $15
Current: $11.78
Upside: +27.33%
Stryker
May 1, 2024
Maintains: Overweight
Price Target: $375 → $380
Current: $334.30
Upside: +13.67%
CONMED
Apr 25, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $67.04
Upside: +41.71%
SI-BONE
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.00
Upside: +92.31%
Insulet
Feb 23, 2024
Maintains: Overweight
Price Target: $250 → $230
Current: $197.19
Upside: +16.64%
Glaukos
Dec 22, 2023
Maintains: Overweight
Price Target: $90 → $105
Current: $118.98
Upside: -11.75%
DexCom
Dec 19, 2023
Maintains: Overweight
Price Target: $135 → $150
Current: $112.49
Upside: +33.35%
Humacyte
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $5.11
Upside: -41.29%
Apyx Medical
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.34
Upside: +235.82%
Boston Scientific
Jul 6, 2023
Maintains: Overweight
Price Target: $58 → $62
Current: $76.55
Upside: -19.01%
Minerva Surgical
May 3, 2023
Maintains: Overweight
Price Target: $100 → $20
Current: $1.48
Upside: +1,251.35%
Zimmer Biomet Holdings
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $106.27
Upside: -
Orchestra BioMed Holdings
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $7.44
Upside: +101.61%
Integer Holdings
Feb 24, 2023
Initiates: Overweight
Price Target: $85
Current: $115.75
Upside: -26.57%
Motus GI Holdings
Nov 15, 2022
Maintains: Overweight
Price Target: $150 → $90
Current: $0.04
Upside: +212,164.15%
AtriCure
Aug 3, 2022
Maintains: Overweight
Price Target: $90 → $55
Current: $22.39
Upside: +145.65%
Medtronic
May 27, 2022
Maintains: Neutral
Price Target: $105 → $100
Current: $77.37
Upside: +29.25%
The Cooper Companies
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $86.51
Upside: +25.71%
Zynex
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $9.07
Upside: -
Baxter International
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $32.85
Upside: -
KORU Medical Systems
Jun 24, 2020
Initiates: Overweight
Price Target: n/a
Current: $2.27
Upside: -